← Leaderboards
Johannes F Fahrmann
University Of Tx Md Anderson Can Ctr
$4,011,689
Attributed
$4,011,689
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$4,011,689 · 3
By mechanism
U01$1,983,279 · 1
R37$1,411,915 · 1
R01$616,495 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Y. Alan Wang$3,748,710
- Dapeng Zhou$1,875,527
- Krishna Pl Bhat$3,427,143
- John V. Heymach$11,138,593
- Nancy U Lin$1,025,163
Others in their field
Other Rising Stars on “Tumor”
- Kenneth Schultz · Trethera Corporation$7,146,643
- Jeff P Simko · Washington University$4,848,843
- Gary G Schwartz · University Of North Dakota$4,000,000
- Yicheng Wang · Immunova Therapeutics, Llc$4,000,000
- David G Brooks · Boston Immune Technologies And Therapeutics, Inc.$3,974,764
- Daniel Francis · Claria Medical, Inc.$3,708,259
Research focus
TumorPlasmaTechnologyPre-ClinicalSuccessTp53 GeneMalignant Breast NeoplasmMitochondriaMass Spectrum AnalysisMouse ModelMalignant NeoplasmsMass Spectrometric ImagingMediatingMetabolicIn VivoImmunocompetentLipidomicsCohortEnzymesImmuneImmunofluorescence ImmunologicImmunophenotypingChemokineCytokine
Grant awards (7)
Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer$672,298
U01 · FY2025 · CA · contact PI
Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions$616,495
R01 · FY2025 · CA · contact PI
Repurposing Glucosylceramide Synthase to Promote Mitochondrial Lethality and Potentiate an Anti-Tumor Immune Response in Triple-Negative Breast Cancer$480,171
R37 · FY2025 · CA · contact PI
Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer$638,683
U01 · FY2024 · CA · contact PI
Repurposing Glucosylceramide Synthase to Promote Mitochondrial Lethality and Potentiate an Anti-Tumor Immune Response in Triple-Negative Breast Cancer$453,927
R37 · FY2024 · CA · contact PI
Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer$672,298
U01 · FY2023 · CA · contact PI
Repurposing Glucosylceramide Synthase to Promote Mitochondrial Lethality and Potentiate an Anti-Tumor Immune Response in Triple-Negative Breast Cancer$477,817
R37 · FY2023 · CA · contact PI